AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) P/B ratio
AbbVie Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 253× (March 2025) — the current reading is the lowest in ten years.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 93.4× | 243.84% |
| FY2023 | 27.2× | 63.37% |
| FY2022 | 16.6× | 7.15% |
| FY2021 | 15.5× | 13.84% |
| FY2020 | 13.6× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 30.8× | 41.12% |
| FY2016 | 21.8× | (10.52%) |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 253×
Ten-year median
17.1×
Current reading's percentile
28
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ABBV AbbVie Inc. | n/m |
| PFE Pfizer Inc. compare | 1.9× |
| AZN AstraZeneca PLC compare | 5.1× |
| NVS Novartis AG compare | 6.6× |
| JNJ Johnson & Johnson compare | 7.7× |
| MRK Merck & Co., Inc. compare | 8.8× |
| GILD Gilead Sciences, Inc. compare | 16.0× |
| AMGN Amgen Inc. compare | 19.2× |
| LLY Eli Lilly and Company compare | 31.2× |
| Drug Manufacturers General industry median | 5.0× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement